Head to Head Review: Neuphoria Therapeutics and Immunic

Comparing the small-cap medical companies Neuphoria Therapeutics and Immunic to determine the better investment option.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Immunic (NASDAQ:IMUX) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap medical companies, but which is the better investment? The article contrasts the two companies based on factors like valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Why it matters

This head-to-head review provides investors with a detailed comparison of two small-cap biotech companies, Immunic and Neuphoria Therapeutics, to help them determine which stock may be the better investment option based on key financial and operational metrics.

The details

The article examines factors like institutional ownership, insider ownership, stock volatility, analyst price targets and recommendations, revenue, earnings, and valuation to assess the relative strengths of Immunic and Neuphoria Therapeutics. It finds that Immunic has stronger institutional ownership, a more favorable analyst consensus, and a lower valuation compared to Neuphoria Therapeutics.

  • The article was published on March 2, 2026.

The players

Immunic, Inc.

A biotechnology company that develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases.

Neuphoria Therapeutics, Inc.

A clinical-stage biotechnology company dedicated to developing therapies that address neuropsychiatric disorders, with a focus on developing BNC210 for the treatment of social anxiety disorder and post-traumatic stress disorder.

Got photos? Submit your photos here. ›

The takeaway

This analysis suggests that Immunic may be the more favorable investment option compared to Neuphoria Therapeutics based on factors like stronger institutional backing, more positive analyst sentiment, and a more attractive valuation. However, investors should continue to monitor the progress and developments of both companies as they advance their respective drug pipelines.